cbdMD price target lowered to $2 from $3 at Maxim

Maxim lowered the firm’s price target on cbdMD (YCBD) to $2 from $3 and keeps a Buy rating on the shares. The firm cites the company’s Q3 loss coming in wider than expected amid softness in demand and regulatory uncertainties, the analyst tells investors in a research note. Maxim adds that while the company has partnered with industry advocacy groups to engage legislators and prioritize compliance with product quality and labeling requirements, it expects regulatory headwinds to persist, limiting growth through 2026.